← Back to Clinical Trials
Recruiting NCT07270614

NCT07270614 Eight-week Sports Injury Prevention Program

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07270614
Status Recruiting
Phase
Sponsor Princess Nourah Bint Abdulrahman University
Condition Health Adult Subjects
Study Type INTERVENTIONAL
Enrollment 30 participants
Start Date 2025-08-16
Primary Completion 2025-12-30

Eligibility & Interventions

Sex Female only
Min Age 18 Years
Max Age 45 Years
Study Type INTERVENTIONAL
Interventions
8-Week Sports Injury Prevention Program

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 30 participants in total. It began in 2025-08-16 with a primary completion date of 2025-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to find out whether an 8-week sports injury prevention program can improve lower-body performance-such as power, agility, and balance-among female college athletes in Saudi Arabia. Sports participation has increased among women in Saudi Arabia, but many injury-prevention programs were originally designed for male athletes and may not meet the specific needs of females. This study will help determine whether a tailored program can reduce injury risks and improve athletic performance. Female athletes aged 18-35 years who have been training and competing for at least one year can participate. Athletes with recent injuries, pregnancy, or chronic medical conditions that could affect performance will not be included. Participants will complete tests before and after the program, including jumping, balance, and agility assessments. The prevention program includes warm-up exercises, stretching, strengthening, jumping drills, balance work, and agility training. By comparing results before and after the program, the study will show whether this type of training can help female athletes stay safer and perform better.

Eligibility Criteria

Inclusion Criteria: * Female athletes aged 18-35 years * Actively participating in organized sports in Saudi Arabia * Minimum of one year of continuous experience in their sport * Currently engaged in regular training and/or competition * Able to perform physical activity safely as confirmed by self-report * Willing to provide informed consent and complete all study assessments Exclusion Criteria: * Any recent injury within the past six months that limits performance * Pregnancy at the time of enrollment * Diagnosis of a chronic medical condition that may affect performance (e.g., uncontrolled diabetes, uncontrolled hypertension) * Any condition that could interfere with safe participation in physical testing or training * Refusal or inability to provide informed consent

Contact & Investigator

Central Contact

Monira Aldhahi, Phd

✉ mialdhahi@pnu.edu.sa

📞 +966506215406

Frequently Asked Questions

Who can join the NCT07270614 clinical trial?

This trial is open to female participants only, aged 18 Years or older, up to 45 Years, studying Health Adult Subjects. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07270614 currently recruiting?

Yes, NCT07270614 is actively recruiting participants. Contact the research team at mialdhahi@pnu.edu.sa for enrollment information.

Where is the NCT07270614 trial being conducted?

This trial is being conducted at Riyadh, Saudi Arabia.

Who is sponsoring the NCT07270614 clinical trial?

NCT07270614 is sponsored by Princess Nourah Bint Abdulrahman University. The trial plans to enroll 30 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology